Countdown to NEWS / NEWS and NEWS, page-3

I'll still back Brazil as our first major signing, they started trial first in Feb 2019 of 100 and stepped it up to trial 750 as announced in November.

Their 9 months are up so Hapvida should have data from 3 months to birth to process now.

Details and snippets below about Hapvida collaboration in Brazil and an idea on what a cash cow this company will be, year in year out.. Numbers based on a realistic 1.5% takeup, which whilst being realistic would be on the low scale of things

Remember these numbers are just from Brazil..

First article is from * from February 2019.
Pregnancy data in real-time

Both parties are collaborating to connect HeraBEAT to Hapvida’s Electronic Medical Record systems, allowing physicians and nurses to monitor data in real time.

HeraMED hopes to become the market leader and sole provider of real time pregnancy data to hospital staff and expecting mothers. It has a strategy of working with top tier healthcare providers and integrating solutions into their workflow, adding revenue for HeraMED via cloud integration and SaaS initiatives.

Based on an “achievable” product uptake of 1.5% in Brazil, HeraMED could generate around $700,000 per month from subscription based fees alone.

It also expects to roll out services across Europe, the US and Australia, which would generate $28 million in device sales alone. The devices are sold for $299 straight to the customer.

Subscription fees of $10.95 per month will be earned through the establishment of HeraCARE, underpinning significant revenue for the company.

HeraMED hopes to not only to sell devices to hospitals and clinics and expecting mums, but also to build an entire platform on top of that which allows either a commercial partner to provide medical consultancy services, like a call center for professionals or an actual healthcare provider.

“The idea is to eventually partner with such entities and be able to offer the unit itself but we want to add a layer of service on top of the hardware in which professionals can have access to this data, these measurements, and analyse that for patients,” Mr Groberman said.

“But it is a pilot,” he added. “They are acquiring 100 units to go under a pilot. We don’t have honestly all the details with regards to how long the pilot will take.”

“We don’t have the licence yet, but the idea is that once that it is proven to be reliable and accurate and efficient, our goal and hope is that … obviously we can then come out to other hospitals.

“We’re already working with in Israel and others, so hopefully we will have a real-life demo and proof in the pudding where it actually works and we have some metrics and the numbers to show how efficient it is.”

article ends...

So 9 months on from the initial purchase of 100 stated above we have stepped up to 750 users across 15 hospitals...  How do you think the initial trial went??

Following article is from Nov 2019..

Hapvida Saude (Brazil) trial update

-   HeraBEAT Smart Foetal monitors with cloud support fully deployed and now being utilised in 15 hospitals and clinics across Brazil

-   Solutions now being trialled with ~750 pregnant women - devices being used for regular visits and during labour as a proven alternative to existing high-cost professional infrastructure

-   Discussions progressing on ROI for scaled Phase II via broadened agreement to include HeraCare

7. November 2019 - Medical technology company, HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company” is pleased to provide the following update on the trial of its HeraBEAT and HeraCARE Pro solution with Hapvida Saude (“Hapvida”. Hapvida is one of Brazil’s largest healthcare providers and hospital owners. The group services over 6.5 million customers nationwide, through a network of approximately 100 hospitals and 1,000 clinics over 11 states.

HeraMED initiated the trial with Hapvida in February 2019 and integrated both its HeraBEAT and HeraCARE Pro cloud support solutions into the group’s hospital system and electronic medical records (EMR) over a four-month period (refer ASX release: 1 July 2019).

Following the integration process, the HeraBEAT and HeraCARE Pro solutions were launched across multiple Hapvida sites (refer ASX release: 28 August 2019). HeraMED advises that both solutions are now fully operational across 15 hospitals and clinics in Hapvida’s network and have been trialled on approximately 750 pregnant women and several thousands of pregnancy monitoring records.

HeraBEAT and HeraCARE are being utilised by Hapvida medical professionals and pregnant women for routine check ups, as well as during the labour. The Company has received ongoing strong positive feedback from, nurses and physicians as well as the technical IT teams and Hapvida management who expressed satisfaction.

The increased expansion and rapid deployment of the trial over 15 sites highlights the value of the Company’s agreement with IntMED (refer ASX release: 2 October 2019), Hapvida’s EMR software developers and  the potential for the solution across large hospital networks and the Company’s ability to scale in a relatively short amount of time. HeraMED remains in ongoing discussions with Hapvida to increase uptake of both the HeraBEAT device and HeraCARE platform across its footprint. The Company will update shareholders as developments materialise.

CEO and Cofounder Mr David Groberman said: “Having progressed from the integration phase to now being operational in 15 individual hospitals and clinics in Hapvida’s network in such a short time frame is a significant achievement for HeraMED.

“The Company has received positive feedback around its solutions from Hapvida’s medical professionals as well as management and we look forward to finalising the trial in the near term. Upon completion, we progress negotiations for a broader roll out of both HeraBEAT and HeraCARE Pro with the group.”

Snapshots of the solutions at fully operational capacity with real time data uploads through IntMED’s software and Hapvida’s EMR are shown below.

"

article ends..

Sell depth looks ready to just pop and disappear, something will spur that on soon enough.

Just an opinion,

TCG